

DAFTAR PUSTAKA

- Agaba, D. C., Migisha, R., Namayanja, R., Katamba, G., Lugobe, H. M., Aheisibwe, H., Twesigomwe, G., & Ashaba, S. (2019). Prevalence and Associated Factors of Metabolic Syndrome among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda. *BioMed Research International*, 2019, e1096201. <https://doi.org/10.1155/2019/1096201>
- Al-Shaar, L., Yuan, C., Rosner, B., Dean, S. B., Ivey, K. L., Clowry, C. M., ... & Rimm, E. B. (2021). Reproducibility and validity of a semiquantitative food frequency questionnaire in men assessed by multiple methods. *American journal of epidemiology*, 190(6), 1122-1132. PubMed: <https://pubmed.ncbi.nlm.nih.gov/33350436/>
- American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care*, 27(2), 596–601. <https://doi.org/10.2337/diacare.27.2.596>
- American Diabetes Association Professional Practice Committee. (2023). Diagnosis and classification of diabetes: Standards of care in diabetes—2024. *Diabetes Care*, 47(Supplement_1), S20–S42. <https://doi.org/10.2337/dc24-S002>
- American Psychiatric Association (2013). *Diagnostic and Statistical Manual of Mental Disorders*, Fifth edition, DSM-5™, p 137-138 . American
- American Psychiatric Association (2024). *What is Schizophrenia*. https://www.psychiatry.org/patients-families/schizophrenia/what-is-schizophrenia#section_1.
- American Psychiatric Association (Ed.). (2010). *Diagnostic and statistical manual of mental disorders: DSM-5* (5 ed.). American Psychiatric Association. 102.
- Arania, R., Triwahyuni, T., Esfandiari, F., & Nugraha, F. R. (2021). Hubungan antara Usia, Jenis Kelamin dan Tingkat Pendidikan dengan Kejadian Diabetes Mellitus di Klinik Mardi Waluyo Lampung Tengah. *Jurnal Medika Malahayati*, 5(3), 146–153. <https://doi.org/10.33024/jmm.v5i3.4200>
- Archibald, L., Brunette, M. F., Wallin, D. J., & Green, A. I. (2019). Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder. *Alcohol Research : Current Reviews*, 40(1), arcr.v40.1.06. <https://doi.org/10.35946/arcr.v40.1.06>
- Aronson, J. K. (Ed.). (2016). *Meyler's side effects of drugs: The international encyclopedia of adverse drug reactions and interactions* (16 ed.). Elsevier. 443-447.
- Bai Y.M, Chen T.T, Liou Y.J, Hong C.J and Tsai S.J (2011). Association between
- Barbosa, M., & Fernandes, V. (2021). Rapid-onset klozapin-induced hyperglycemia: Pathways of glycaemic dysregulation. *BMJ Case Reports*, 14(9), e243938. <https://doi.org/10.1136/bcr-2021-243938>
- Bermudez, V., Olivar, L. C., Torres, W., Navarro, C., Gonzalez, R., Espinoza, C.,

- Morocho, A., Mindiola, A., Chacin, M., Arias, V., Añez, R., Salazar, J., Riaño-Garzon, M., Diaz-Camargo, E., Bautista, M. J., & Rojas, J. (2019). Cigarette smoking and metabolic syndrome components: A cross-sectional study from Maracaibo City, Venezuela. *F1000Research*, 7, 565. <https://doi.org/10.12688/f1000research.14571.3>
- Bobes, J., Arango, C., Garcia-Garcia, M., Rojas, J., & CLAMORS Study Collaborative Group. (2010). Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study. *The Journal of Clinical Psychiatry*, 71(3), 280–286. <https://doi.org/10.4088/JCP.08m04250yel>
- Cai J, Yi Z, Lu W, Fang Y and Zhang C . (2013). Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction. *Medical Hypotheses* 80 (2013) 486-489
- Centorrino, F., Fogarty, K. V., Sani, G., Salvatore, P., Cincotta, S. L., Hennen, J., Guzzetta, F., Talamo, A., Saadeh, M. G., & Baldessarini, R. J. (2005). Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. *Human Psychopharmacology: Clinical and Experimental*, 20(7), 485–492. <https://doi.org/10.1002/hup.719>
- Chen J, Huang X.F, Shao R, Chen C and Deng C. (2017), Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes, *Drug-Induced Diabetes. Front. Neurosci. Review*, 11:643.doi: 10.3389/fnins.2017.00643
- Chen, Y., Wang, Y., Fang, X., Zhang, Y., Song, L., & Zhang, C. (2020). Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: A meta-analysis. *General Psychiatry*, 33(3), e100192. <https://doi.org/10.1136/gpsych-2020-100192>
- Chisholm-Burns, M. A., Schwinghammer, T. L., Wells, B. G., Malone, P. M., Kolesar, J. M., & DiPiro, J. T. (2016). *Pharmacotherapy Principles and Practice* (4 ed.). McGraw-Hill Education. 651-678.
- Choi, D.-W., Jeon, J., Lee, S. A., Han, K.-T., Park, E.-C., & Jang, S.-I. (2018). Association between Smoking Behavior Patterns and Glycated Hemoglobin Levels in a General Population. *International Journal of Environmental Research and Public Health*, 15(10), 2260. <https://doi.org/10.3390/ijerph15102260>
- Chokhawala, K., & Stevens, L. (2021). Antipsychotic Medications. Dalam *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK519503/>
- Cloutier, M., Aigbogun, M. S., Guerin, A., Nitulescu, R., Ramanakumar, A. V., Kamat, S. A., DeLucia, M., Duffy, R., Legacy, S. N., Henderson, C., Francois, C., & Wu, E. (2016). The Economic Burden of Schizophrenia in the United States in 2013. *The Journal of Clinical Psychiatry*, 77(6), 764–771. <https://doi.org/10.4088/JCP.15m10278>
- Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. A. (2017). Antipsychotic-associated weight gain: Management

- strategies and impact on treatment adherence. *Neuropsychiatric Disease and Treatment*, 13, 2231–2241. <https://doi.org/10.2147/NDT.S113099>
- De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., Orsolini, L., Martinotti, G., & Di Giannantonio, M. (2018). Safety of antipsychotics for the treatment of schizophrenia: A focus on the adverse effects of klorazepin. *Therapeutic Advances in Drug Safety*, 9(5), 237–256. <https://doi.org/10.1177/2042098618756261>
- Dickerson, F. B. & Lehman, A. F. (2011). Evidence-based psychotherapy for schizophrenia: 2011 update. *J Nerv Ment Dis*, 199, 520-6.
- Dinan, T. G. (2004). Stress and the genesis of diabetes mellitus in schizophrenia.
- Dipiro, J.T., Talbert, R.L., N Yee, G.C., Maztke, G.R., Wells, B.G., Posey, L.M., (2015). *Pharmacotherapy A Pathophysiologic Approach*, Nine Edition, Mc. Graw-Hill Medical Publishing Division, New York, 1209-1210; 1213- 1217; 1221
- Godlewska B.R., Hilkesberger L.O., Ciwoniuk M., Olajossy M., Michalowska
- Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., Collier, H. A., Dipaola, R. S., Gelinas, C., Rabinowitz, J. D., & White, E. (2011). Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. *Genes & Development*, 25(5), 460–470. <https://doi.org/10.1101/gad.2016311>
- H.M. Limon J., and Landowski J. (2009). Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene, *The Pharmacogenomics Journal* 9 (4): 234-241
- Haddad P. (2005). Weight Change With Atypical Antipsychotics in the Treatment of Schizophrenia. *J Psychopharmacol.*; 19(6): 16-27.
- Haidary, H. A., & Padhy, R. K. (2021). Klorazepin. Dalam *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK535399/>
- Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000). Klorazepin, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. *The American Journal of Psychiatry*, 157(6), 975–981. <https://doi.org/10.1176/appi.ajp.157.6.975>
- Hill, M.J & Reynolds, G.P. (2011). Functional consequences of two HTR2C
- Hovestadt, I., Kiess, W., Lewien, C., Willenberg, A., Poulain, T., Meigen, C., Körner, A., & Vogel, M. (2022). HbA1c percentiles and the association between BMI, age, gender, puberty, and HbA1c levels in healthy German children and adolescents. *Pediatric Diabetes*, 23(2), 194–202. <https://doi.org/10.1111/pedi.13297>
- HTR2C polymorphisms and metabolic syndrome in patients with <https://doi.org/10.1192/bjp.184.47.s72>
- Howes, O., McCutcheon, R., & Stone, J. (2015). Glutamate and dopamine in schizophrenia: An update for the 21st century. *Journal of psychopharmacology (Oxford, England)*, 29(2), 97–115. <https://doi.org/10.1177/0269881114563634>

- Ijaz S, Bolea B, Davis S, Savovic J, Richards A, Sullivan S, and Moran P, (2018). Antipsychotic Polypharmacy and Metabolic Syndrome in Schizophrenia : a Review of Systematic Reviews, *BMC Psychiatry* 18 : 275, doi : 10.1186/s12888-018-1848y
- Ikawati, Z. (2018). *Tata Laksana Terapi Penyakit Sistem Syaraf Pusat (Pertama)*. Bursa Ilmu. 249-280
- Ilhamsyah, R. (2015). Pengaruh pajanan asap rokok terhadap kejadian kanker payudara (S1 thesis, Universitas Muhammadiyah Yogyakarta). Universitas Muhammadiyah Yogyakarta Repository. <https://etd.umy.ac.id/id/eprint/20189>
- Instituto Federal de Educacao (2018). *PCR Protocol for Taqman® Genotyping Assays*, <https://dx.doi.org/10.17504/protocols.io.sfzebp6>
- Irawan, D. (2010). *Prevalensi dan Faktor Risiko Kejadian Diabetes Melitus Tipe 2 di Daerah Urban Indonesia (Analisis Data Sekunder Riskesdas 2007)* [Universitas Indonesia]. <https://lib.ui.ac.id>
- Ishikawa, S., Yamamura, R., Hashimoto, N., Okubo, R., Sawagashira, R., Ito, Y. M., Sato, N., & Kusumi, I. (2022). The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 113, 110453. <https://doi.org/10.1016/j.pnpbp.2021.110453>
- Ju, Z., Zheng, X., Huang, J., Qi, C., Zhang, Y., Li, J., Zhong, J., & Wang, C. (2012). Functional characterization of genetic polymorphisms identified in the promoter region of the bovine PEPS gene. *DNA and Cell Biology*, 31(6), 1038–1045. <https://doi.org/10.1089/dna.2011.1555>
- Kemenkes (2018). *Riset Kesehatan Dasar*, Jakarta, Kementerian Kesehatan Republik Indonesia.
- Kemenkes (2023). Survei Kesehatan Indonesia 2023, Badan Kebijakan Pembangunan Indonesia, <https://www.badankebijakan.kemkes.go.id/hasil-ski-2023/>, diakses tanggal 18 Juli 2024.
- Kew, J. N. & Kemp, J. A. (2005). Ionotropic and metabotropic glutamate receptor structure and pharmacology. *Psychopharmacology (Berl)*, 179, 4-29.
- Kim, M., Yang, S. J., Kim, H. H., Jo, A., Jhon, M., Lee, J.-Y., Ryu, S.-H., Kim, J.-M., Kweon, Y.-R., & Kim, S.-W. (2023). Effects of Dietary Habits on General and Abdominal Obesity in Community-dwelling Patients with Schizophrenia. *Clinical Psychopharmacology and Neuroscience*, 21(1), 68–76. <https://doi.org/10.9758/cpn.2023.21.1.68>
- Klemettila J. P., (2016). Metabolic Adverse Effects in Klorazepin-Treated Patients with Schizophrenia : Cytokine and Adipokine Alterations, Neuropeptide Y, and Genetic Associations, *Academic Dissertation*, University of Tampere, Finland
- Koller, E., Schneider, B., Bennett, K., & Dubitsky, G. (2001). Klorazepin-associated diabetes. *The American Journal of Medicine*, 111(9), 716–723. [https://doi.org/10.1016/s0002-9343\(01\)01000-2](https://doi.org/10.1016/s0002-9343(01)01000-2)

- Kring, S. I. I., Werge, T., Holst, C., Toubro, S., Astrup, A., Hansen, T., Pedersen, O., & Sørensen, T. I. A. (2009). Polymorphisms of Serotonin Receptor 2A and 2C Genes and COMT in Relation to Obesity and Type 2 Diabetes. *PLoS ONE*, 4(8), e6696. <https://doi.org/10.1371/journal.pone.0006696>
- Krivoy, A., Gaughran, F., Weizman, A., Breen, G., & MacCabe, J. H. (2016). Gene polymorphisms potentially related to the pharmacokinetics of klorazepin: A systematic review. *International Clinical Psychopharmacology*, 31(4), 179–184. <https://doi.org/10.1097/YIC.0000000000000065>
- Kumar, P., Mishra, D. K., Mishra, N., Ahuja, S., Raghuvanshi, G., & Niranjana, V. (2019). Acute onset klorazepin-induced hyperglycemia: A case report. *General Psychiatry*, 32(2), e100045. <https://doi.org/10.1136/gpsych-2018-100045>
- Laboratorium Penelitian Terpadu Fakultas Farmasi Universitas Ahmad Dahlan. (2022), Workshop Konsep Dasar Genomik dan Farmakogenomik, 3-4 Juni 2022, *Buku Petunjuk Workshop Farmakogenomik*, Yogyakarta
- Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). *Drug Information Handbook* (17th edition). Lexi-Comp Inc.
- Lally, J. & Maccabe, J. H. (2015). Antipsychotic Medication In Schizophrenia: A Review. *British Medical Bulletin*, 114, 169-179
- Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: A review. *British Medical Bulletin*, 114(1), 169–179. <https://doi.org/10.1093/bmb/ldv017>
- Lambert, B., Cunningham, F., Miller, D., Dalack, G., & Hur, K. (2006). Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia. *American Journal of Epidemiology*, 164, 672–681. <https://doi.org/10.1093/aje/kwj289>
- Lang, A., Kuss, O., Filla, T., & Schlesinger, S. (2021). Association between per capita sugar consumption and diabetes prevalence mediated by the body mass index: Results of a global mediation analysis. *European Journal of Nutrition*, 60(4), 2121–2129. <https://doi.org/10.1007/s00394-020-02401-2>
- Lavretsky, H. (2008). History of Schizophrenia as a Psychiatric Disorder. Dalam *Clinical Handbook of Schizophrenia* (hlm. 3–12). Guilford Press.
- Lee J and Kim M.S. (2007). The role of GSK3 in glucose homeostasis and the development of insulin resistance, *Diabetes Research and Clinical Practice* 77S (2007) S49–S57, Elsevier
- Lee, J. S., Yun, J.-Y., Kang, S. H., Lee, S. J., Choi, J.-H., Nam, B., Lee, S.-H., Chung, Y.-C., & Kim, C.-H. (2020). Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms. *Clinical Psychopharmacology and Neuroscience*, 18(3), 386–394. <https://doi.org/10.9758/cpn.2020.18.3.386>
- Lehman, A. F. et al. (2010) „Practice Guideline for the Treatment of Patients With Schizophrenia“, American Psychiatric Association, (February), pp. 1–184

- Leslie, D. L., & Rosenheck, R. A. (2004). Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. *The American Journal of Psychiatry*, 161(9), 1709–1711. <https://doi.org/10.1176/appi.ajp.161.9.1709>
- Li, X., Zhou, W., & Yi, Z. (2022). A glimpse of gender differences in schizophrenia. *General Psychiatry*, 35(4), e100823. <https://doi.org/10.1136/gpsych-2022-100823>
- Liu, X., Wu, Z., Lian, J., Hu, C.-H., Huang, X.-F., & Deng, C. (2017). Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic klorazapin or olanzapine treatment in rats. *Scientific Reports*, 7, 2762. <https://doi.org/10.1038/s41598-017-02884-w>
- Luvannyam, E., Jain, M. S., Pormento, M. K. L., Siddiqui, H., Balagtas, A. R. A., Emuze, B. O., & Poprawski, T. (n.d.). Neurobiology of Schizophrenia: A Comprehensive Review. *Cureus*, 14(4), e23959. <https://doi.org/10.7759/cureus.23959>
- MacNeil, R. R., & Müller, D. J. (2016). Genetics of Common Antipsychotic-Induced Adverse Effects. *Molecular Neuropsychiatry*, 2(2), 61–78. <https://doi.org/10.1159/000445802>
- Medrano, R. & Oliveira, C. (2014). Guidelines for the Tetra-Primer ARMS–PCR Technique Development. *Molecular Biotechnology* 56, 599-608.
- Meltzer, H., Gatward, R., Goodman, R., & Ford, T. (2003). Mental health of children and adolescents in Great Britain. *International Review of Psychiatry (Abingdon, England)*, 15(1–2), 185–187. <https://doi.org/10.1080/0954026021000046155>
- Mercer NJ. (2013). New Treatment Approaches for Schizophrenia. Division of Schizophrenia Research University of Medicine and Dentistry of New Jersey. *NAMI*. Feb. 19. 2013 7:30.
- Miller DD, Ellingrod VL, Holman TL, *et al.* (2005). Klorazapin induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. *Am J Med Genet.*;133B(1): 97-100.
- Modesti, M. N., Arena, J. F., Palermo, N., & Del Casale, A. (2023). A Systematic Review on Add-On Psychotherapy in Schizophrenia Spectrum Disorders. *Journal of Clinical Medicine*, 12(3), 1021. <https://doi.org/10.3390/jcm12031021>
- Mohammad Hosseinzadeh, F., Hosseinzadeh-Attar, M. J., Yekaninejad, M. S., & Rashidi, B. (2016). Effects of selenium supplementation on glucose homeostasis and free androgen index in women with polycystic ovary syndrome. *Journal of Trace Elements in Medicine and Biology: Organ of the Society for Minerals and Trace Elements (GMS)*, 34, 56–61. <https://doi.org/10.1016/j.jtemb.2016.01.002>

- Mordarska, K., & Godziejewska-Zawada, M. (2017). Diabetes in the elderly. *Przegląd Menopauzalny = Menopause Review*, 16(2), 38. <https://doi.org/10.5114/pm.2017.68589>
- Montastruc, F., Palmaro, A., Bagheri, H., Schmitt, L., Montastruc, J. L., & Lapeyre-Mestre, M. (2015). Role of serotonin 5-HT_{2C} and histamine H₁ receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase. *European Neuropsychopharmacology*, 25(10), 1556-1565. <https://doi.org/10.1016/j.euroneuro.2015.07.010>
- Mouri, Mi., & Badireddy, M. (2022). Hyperglycemia. Dalam *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK430900/>
- Mu, X., Wu, W., Wang, S., Su, X., Guan, H., Guan, X., Lu, X., & Li, Z. (2024). Smoking affects symptom improvement in schizophrenia: A prospective longitudinal study of male patients with first-episode schizophrenia. *Schizophrenia*, 10(1), 34. <https://doi.org/10.1038/s41537-024-00449-1>
- Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. *American Family Physician*, 81(5), 617–622.
- Mulder, H., Franke, B., Van der, A.V. B. V., Arends, J., Wilmink, F.W., Scheffer, H., Egberts, A.C.G., (2007). The Association Between HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia. *J Clin Psychopharmacol* 2007(27), pp.338–343.
- Neyshaburinezhad, N., Ghasim, H., Rouini, M., Daali, Y., & Ardakani, Y. H. (2021). Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations. Review of the Human Data. , 11(8), 804. <https://doi.org/10.3390/jpm11080804>
- Nonogaki, K. (2022). The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases. *International Journal of Molecular Sciences*, 23(3), 1600. <https://doi.org/10.3390/ijms23031600>
- Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L. E., Hu, Y., Maayan, N., & Adams, C. E. (2017). Antipsychotic combinations for schizophrenia. *The Cochrane Database of Systematic Reviews*, 2017(6), CD009005. <https://doi.org/10.1002/14651858.CD009005.pub2>
- Pahlawati, A., & Nugroho, P. S. (2019). Hubungan Tingkat Pendidikan dan Usia dengan Kejadian Diabetes Melitus di Wilayah Kerja Puskesmas Palaran Kota Samarinda Tahun 2019. *Borneo Student Research (BSR)*, 1(1), 1–5.
- Panariello F., De Luca V., and De Bartolomeis A., (2009). *Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies. Review Article*. Hindawi Publishing Corporation. Schizophrenia Research and Treatment Vol. 2011(2011): 16
- Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options. *Pharmacy and Therapeutics*, 39(9), 638–64
- Perkins, D. O., Gu, H., Boteva, K., & Lieberman, J. A. (2005). Relationship between

- duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. *The American Journal of Psychiatry*, 162(10), 1785–1804. <https://doi.org/10.1176/appi.ajp.162.10.1785>
- Perwitasari D.A. (2016). *Farmakogenetik Asuhan Kefarmasian Menuju Individualisasi Terapi*. UAD Press. Yogyakarta: (64-66).
- Petersen, M. C., & Shulman, G. I. (2018). Mechanisms of Insulin Action and Insulin Resistance. *Physiological Reviews*, 98(4), 2133–2223. <https://doi.org/10.1152/physrev.00063.2017>
- Raedler, T. J. (2010). Cardiovascular aspects of antipsychotics. *Curr Opin Psychiatry*, 23, 574-81.
- Ramaswamy, V., Cresence, V. M., Rejitha, J. S., Lekshmi, M. U., Dharsana, K. S., Prasad, S. P., & Vijila, H. M. (2007). Listeria—Review of epidemiology and pathogenesis. *Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi*, 40(1), 4–13.
- Reynolds G.P, Kirk SL. (2010). Metabolic Side Effects of Antipsychotic Drug Treatment- Pharmacological Mechanisms. *Pharmacol Ther.*; 125(1): 169-179.
- Reynolds G.P.,(2012). Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review. *Clinical Psychopharmacology and Neuroscience.*;10(2):71-77
- Reynolds, G. P., Yevtushenko, O. O., Gordon, S., Arranz, B., San, L., & Cooper, S. J. (2013). The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. *International Journal of Neuropsychopharmacology*, 16(6), 1421-1425. <https://doi.org/10.1017/S1461145712001435>
- Rini, S. (2015). Sindrom Metabolik. *J Majority*, 4(4), 88–93
- Riordan HJ, Antonini P, and Murphy MF, (2011), Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring & Healthcare Implications, Review Article, *American Health & Drug Benefits*, 4 (5): 292 – 302
- Rodriquez A. P, Pozo K.T, Lewczuk K and Rada F.M. (2015). Atypical antipsychotics and metabolic syndrome, Review article, *Cardiology Endocrinology*, 4:132–137
- Ryu, S. *et al.* (2007) „– 759 C / T polymorphism of 5-HT_{2C} receptor gene and early phase weight gain associated with antipsychotic drug treatment“, *Prog Neuropsychopharmacol Biol Psychiatry* 31, pp. 673–677.
- Sadiq, S., Anwar, M. Z., Shafique, H., Manzoor, S. M., Shoaib, S., Hamid, R., Hashmi, S. N., Ashraf, N. M., Afsar, T., Bhat, M. A., & Razak, S. (2024). Determination of IL-6 gene promoter polymorphism in patients with hepatitis C and its impact on RNA secondary structure. *Medicina*, 60(3), 368. <https://doi.org/10.3390/medicina60030368>

- Šagud, M., Vuksan-Ćusa, B., Jakšić, N., Mihaljević-Peš, A., Živković, M., Vlatković, S., Prgić, T., Marčinko, D., & Wang, W. (2018). Nicotine dependence in Croatian male inpatients with schizophrenia. *BMC Psychiatry*, 18(1), 18. <https://doi.org/10.1186/s12888-018-1606-1>
- Saha, S., & González-Maeso, J. (2023). The crosstalk between 5-HT2AR and mGluR2 in schizophrenia. *Neuropharmacology*, 230, 109489. <https://doi.org/10.1016/j.neuropharm.2023.109489>
- schizophrenia treated with atypical antipsychotics, *Schizophrenia Research*
- Sernyak, M. J., Leslie, D. L., Alarcon, R. D., Losonczy, M. F., & Rosenheck, R. (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. *The American Journal of Psychiatry*, 159(4), 561–566. <https://doi.org/10.1176/appi.ajp.159.4.561>
- Setiawan, M. (2011) „Pre-diabetes dan peran HbA1c dalam diagnosis dan skreening diabetes mellitus“, *Jurnal Saintika Madeika*, 7(14), pp. 57–64.
- Sherwood, L. (2012). *Fisiologi Manusia dari Sel ke Sistem*. Edisi 6. Jakarta : EGC. h. 708-710
- Sicard MN, Zai CC, Tiwari AK, *et al.* (2010). Polymorphisms of the 5HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. *Pharmacogenomics*;11(11): 1561-1571.
- Sigit, F. S., Tahapary, D. L., Trompet, S., Sartono, E., Willems van Dijk, K., Rosendaal, F. R., & de Mutsert, R. (2020). The prevalence of metabolic syndrome and its association with body fat distribution in middle-aged individuals from Indonesia and the Netherlands: A cross-sectional analysis of two population-based studies. *Diabetology & Metabolic Syndrome*, 12, 2. <https://doi.org/10.1186/s13098-019-0503-1>
- Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current Concepts and Treatments of Schizophrenia. *Molecules (Basel, Switzerland)*, 23(8), E2087. <https://doi.org/10.3390/molecules23082087>
- Stroup, T. S., & Gray, N. (2018). Management of common adverse effects of antipsychotic medications. *World Psychiatry*, 17(3), 341–356. <https://doi.org/10.1002/wps.20567>
- Suastika, K., Dwipayana, P., Semadi, M. S., & Kuswardhani, R. A. T. (2012). Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases. *Intech Open*. <http://dx.doi.org/10.5772/52397>
- Suetani R.J, Siskind D, Reichhold H, and Kisely S. (2017), Genetic Variants Impacting Metabolic Oucomes among People on Klorazepin : A Systematic Review and Meta-Analysis, *Psychopharmacology* 234: 2989-3008. doi 10.1007/s00213-017-4728-0

- Strauss, J., Witoelar, F., & Sikoki, B. (2016). The fifth wave of the Indonesia Family Life Survey: Overview and field report (Vol. 1). RAND Corporation. https://www.rand.org/pubs/working_papers/WR1143z1.html
- Tosur, M., Viau-Colindres, J., Astudillo, M., Redondo, M. J., & Lyons, S. K. (2020). Medication-induced hyperglycemia: Pediatric perspective. *BMJ Open Diabetes Research & Care*, 8(1), e000801. <https://doi.org/10.1136/bmjdr-2019-000801>
- Tovey, E., Rampes, H., & Livingstone, C. (2005). Klozapin-induced type-2 diabetes mellitus: Possible mechanisms and implications for clinical practice. *Journal of psychopharmacology (Oxford, England)*, 19, 207–210. <https://doi.org/10.1177/0269881105049043>
- Ulcickas Yood, M., Delorenze, G. N., Quesenberry, C. P., Oliveria, S. A., Tsai, A.-L., Kim, E., Cziraky, M. J., McQuade, R. D., Newcomer, J. W., & L'italien, G. J. (2011). Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: Does the effect differ by dose? *BMC Psychiatry*, 11, 197. <https://doi.org/10.1186/1471-244X-11-197>
- Usman, J., Rahman, D., & Sulaiman, N. (2020). Faktor yang Berhubungan dengan Kejadian Diabetes Mellitus pada Pasien di RSUD Haji Makassar. *Jurnal Komunitas Kesehatan Masyarakat*, 2(1), 16–22
- Vasudev K, Choi YH, Norman R, Kim RB, and Schwarz UI, (2017), Genetic Determinants of Klozapin-Induced Metabolic Side Effects, *The Canadian Journal of Psychiatry*, vol 62(2), 138-149, doi: 10.1177/0706743716670128
- Ventriglio, A., Baldessarini, R. J., Vitani, G., Bonfitto, I., Cecere, A. C., Rinaldi, A., Petito, A., & Bellomo, A. (2018). Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics. *Frontiers in Psychiatry*, 9, 744. <https://doi.org/10.3389/fpsyt.2018.00744>
- Vittinghoff, E., Shiboski, S. C., Glidden, D. V., & McCulloch, C. E. (2005). Regression methods in biostatistics: Linear, logistic, survival, and repeated measures models. Springer Science+Business Media.
- Wagman A.S, Johnson K.W, Bussiere D. E. (2004). Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes. *Current Pharmaceutical Design*, 2004, 10, 1105-1137 Bentham Science Publishers Ltd.
- Wang, C. K., Aleksic, A., Xu, M. S., Procyshyn, R. M., Ross, C. J., Vila- Rodriguez, F., Ramos-Miguel, A., Yan, R., Honer, W. G. & Barr, A. M. (2016). A Tetra-Primer Amplification Refractory System Technique for the Cost-Effective and Novel Genotyping of Eight Single-Nucleotide Polymorphisms of the Catechol-O-Methyltransferase Gene. *Genetic Testing and Molecular Biomarkers*, 20, 465-470.
- Wang, P. S., Glynn, R. J., Ganz, D. A., Schneeweiss, S., Levin, R., & Avorn, J. (2016). Klozapin use and risk of diabetes mellitus. *Journal of Clinical Psychopharmacology*, 22(3), 236–243. <https://doi.org/10.1097/00004714-200206000-00002>

- Wani, R. *et al.* (2015) „Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment“, *Journal of Neurosciences in Rural Practice*, 6(1), p. 17.
- WHO, (2018). *Schizophrenia*. Online. Available at: <https://www.who.int/news-room/fact-sheets/detail/schizophrenia>. [Accessed 17 07 2019].
- WHO, (2023). *International Classification of Diseases 11 th (ICD-11)*, <https://icd.who.int/en>, [accessed 07 03 2023].
- Willi, C., Bodenmann, P., Ghali, W. A., Faris, P. D., & Cornuz, J. (2007). Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. *JAMA*, 298(22), 2654–2664. <https://doi.org/10.1001/jama.298.22.2654>
- Yevtushenko, O. O. *et al.* (2008) „Influence of 5-HT 2C receptor and leptin gene polymorphisms , smoking and drug treatment on metabolic disturbances in patients with schizophrenia“, *Br J Psychiatry* 2008 Jun;192(6):424-8. doi: 10.1192/bjp.bp.107.041723.
- Yuan, C., Spiegelman, D., Rimm, E. B., Rosner, B. A., Stampfer, M. J., Barnett, J. B., & Willett, W. C. (2017). Validity of a dietary questionnaire assessed by comparison with multiple weighed dietary records or 24-hour recalls. *American journal of epidemiology*, 185(7), 570-584. PubMed: <https://pubmed.ncbi.nlm.nih.gov/28338828/>
- Yuan, C., Spiegelman, D., Rimm, E. B., Rosner, B. A., Stampfer, M. J., Barnett, J. B., & Willett, W. C. (2018). Relative validity of nutrient intakes assessed by questionnaire, 24-hour recalls, and diet records as compared with urinary recovery and plasma concentration biomarkers: findings for women. *American journal of epidemiology*, 187(5), 1051-1063. PubMed: <https://pubmed.ncbi.nlm.nih.gov/29036411/>
- Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W and Nonaka K, (2000), Identification of polymorphic loci in the promoter region of the serotonin 5-HT 2C receptor gene and their association with obesity and Type II diabetes, Short Communication, *Diabetologia* 43 : 373-376, Springer-Verlag2000
- Yücel, Y., Coşkun, S., Cengiz, B., Özdemir, H. H., Uzar, E., Çim, A., Camkurt, M. A., & Aluclu, M. U. (2016). Association of Polymorphisms within the Serotonin Receptor Genes 5-HTR1A, 5-HTR1B, 5-HTR2A and 5-HTR2C and Migraine Susceptibility in a Turkish Population. *Clinical Psychopharmacology and Neuroscience*, 14(3), 250–255. <https://doi.org/10.9758/cpn.2016.14.3.250>
- Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021). A Focused Review of the Metabolic Side-Effects of Klorazepin. *Frontiers in Endocrinology*, 12, 67. <https://doi.org/10.3389/fendo.2021.609240>
- Zhang, Y., Liu, Y., Su, Y., You, Y., Ma, Y., Yang, G., Song, Y., Liu, X., Wang, M., Zhang, L., & Kou, C. (2017). The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: A network meta-analysis. *BMC Psychiatry*, 17, 373. <https://doi.org/10.1186/s12888-017-1539-0>.